Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
SNN 
Smith & Nephew SNATS Inc (SNN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: SNN (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $37.03
1 Year Target Price $37.03
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.81% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.21B USD | Price to earnings Ratio 30.16 | 1Y Target Price 37.03 |
Price to earnings Ratio 30.16 | 1Y Target Price 37.03 | ||
Volume (30-day avg) 4 | Beta 0.66 | 52 Weeks Range 23.11 - 38.47 | Updated Date 12/6/2025 |
52 Weeks Range 23.11 - 38.47 | Updated Date 12/6/2025 | ||
Dividends yield (FY) 2.28% | Basic EPS (TTM) 1.11 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.26% | Operating Margin (TTM) 14.49% |
Management Effectiveness
Return on Assets (TTM) 5.81% | Return on Equity (TTM) 9.14% |
Valuation
Trailing PE 30.16 | Forward PE 12.3 | Enterprise Value 16752952815 | Price to Sales(TTM) 2.39 |
Enterprise Value 16752952815 | Price to Sales(TTM) 2.39 | ||
Enterprise Value to Revenue 2.82 | Enterprise Value to EBITDA 12.61 | Shares Outstanding 424412010 | Shares Floating 866064268 |
Shares Outstanding 424412010 | Shares Floating 866064268 | ||
Percent Insiders 0.04 | Percent Institutions 7.69 |
Upturn AI SWOT
Smith & Nephew SNATS Inc
Company Overview
History and Background
Smith & Nephew was founded in 1856 in Hull, England. While Smith & Nephew does have a US presence through Smith & Nephew, Inc, SNATS Inc (Smith & Nephew Advanced Technology Solutions, Inc.) doesn't trade independently on the US stock exchange. Smith & Nephew (SN.) is listed on the London Stock Exchange (LSE). The analysis will proceed from the perspective of the overall Smith & Nephew Group and its activities in the US.
Core Business Areas
- Orthopaedics: Focuses on joint reconstruction, sports medicine, trauma, and extremities. Products include hip and knee implants, arthroscopic technologies, and fracture management systems.
- Advanced Wound Management: Offers a range of products for wound healing, including advanced wound dressings, negative pressure wound therapy, and bioactives.
- Sports Medicine & ENT: Develops and markets minimally invasive surgical products for sports medicine procedures and ENT (Ear, Nose, and Throat) conditions.
Leadership and Structure
The leadership team is headed by a CEO and includes various executive officers responsible for finance, operations, R&D, and commercial activities. The organizational structure is typically hierarchical, with regional and functional divisions.
Top Products and Market Share
Key Offerings
- Allevyn (Advanced Wound Dressings): A leading brand of advanced wound dressings used for chronic and acute wounds. The wound care market is competitive with key players like 3M (MMM) and Convatec (CTEC.L). Market share varies by region but is significant.
- Polaris (Arthroscopic Enabling Technology): A comprehensive visualization platform used in arthroscopic surgery, enabling advanced procedures. Competitors include Stryker (SYK) and Arthrex.
- Trilogy (Hip Implants): Hip implant system designed to restore mobility and reduce pain. Competitors include Zimmer Biomet (ZBH) and DePuy Synthes (JNJ).
Market Dynamics
Industry Overview
The medical technology industry is driven by innovation, aging populations, and increasing demand for minimally invasive procedures. It is highly regulated and competitive.
Positioning
Smith & Nephew is a major player in the orthopaedics, advanced wound management, and sports medicine markets. Its competitive advantages include a strong brand reputation, a broad product portfolio, and a global distribution network.
Total Addressable Market (TAM)
The total addressable market for Smith & Nephew's core segments (orthopaedics, wound care, sports medicine) is estimated to be in the hundreds of billions of dollars globally. Smith & Nephew is well-positioned with a significant market share in these key segments.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Global distribution network
- Diverse product portfolio
- Focus on innovation
- Established relationships with healthcare providers
Weaknesses
- Exposure to regulatory changes
- Intense competition
- Product liability risks
- Currency fluctuations
- Reliance on acquisitions for growth
Opportunities
- Expanding into emerging markets
- Developing new technologies and products
- Acquiring smaller companies with complementary technologies
- Partnering with healthcare providers to offer integrated solutions
- Leveraging digital technologies to improve patient outcomes
Threats
- Increasing pricing pressure from healthcare providers
- Technological disruption from new entrants
- Product recalls
- Changes in reimbursement policies
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- ZBH
- SYK
- BSX
Competitive Landscape
Smith & Nephew's competitive advantages include its specialized product portfolio and brand recognition. Disadvantages include its smaller size compared to some competitors and reliance on specific market segments.
Major Acquisitions
Osiris Therapeutics
- Year: 2019
- Acquisition Price (USD millions): 660
- Strategic Rationale: Expanded Smith & Nephew's regenerative medicine portfolio.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on London Stock Exchange financial filings (SN.).
Future Projections: Analyst estimates available from financial news sources and investment research firms (FactSet, Bloomberg) focused on the London Stock Exchange. No specific data is provided here.
Recent Initiatives: Recent initiatives may include new product launches, acquisitions, and partnerships. Consult company press releases and investor presentations from Smith & Nephew. No specific data is provided here.
Summary
Smith & Nephew is a well-established medical technology company with a strong position in its core markets. Its strengths include a diverse product portfolio and global reach. However, it faces intense competition and regulatory challenges. Growth will depend on continued innovation and strategic acquisitions.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Smith & Nephew Investor Relations
- Financial News Outlets
- Market Research Reports
- London Stock Exchange (LSE) filings
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary depending on the source. Financial data requires access to London Stock Exchange filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Smith & Nephew SNATS Inc
Exchange NYSE | Headquaters - | ||
IPO Launch date 1999-11-16 | CEO & Director Dr. Deepak S. Nath Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17000 | Website https://www.smith-nephew.com |
Full time employees 17000 | Website https://www.smith-nephew.com | ||
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.